Send me real-time posts from this site at my email

Why Sierra Oncology Stock Is On Fire Today

What happened

Shares of the clinical-stage biotech Sierra Oncology (NASDAQ: SRRA) jumped by as much as 90% in premarket trading Tuesday. Investors are piling into this small-cap biotech stock today in response to overwhelmingly positive late-stage trial results for the blood cancer drug candidate momelotinib.

Specifically, Sierra announced ahead of the opening bell Tuesday morning that momelotinib met all of its primary and secondary endpoints in a phase 3 trial as a treatment for myelofibrosis patients who are symptomatic and anemic and were previously treated with an approved JAK inhibitor. Sierra licensed momelotinib from Gilead Sciences in 2018 for a meager $3 million upfront payment.

Image source: Getty Images.

So what

As a second-line therapy for myelofibrosis, Sierra's momelotinib probably won't hit blockbuster level sales for this first indication. However, this target market is large enough for the drug to conceivably haul in upward of $750 million at peak. And a peak sales estimate of around $500 million for this indication is probably a safe bet. Either of these peak sales figures would be a substantial revenue stream for a company valued at under $350 million as of yesterday's closing bell.

Now what

Sierra plans on filing for the drug's approval with the Food and Drug Administration in the second quarter of 2022. So, if everything goes according to plan, momelotinib ought to be commercially available no later than the first quarter of 2023.

Should investors buy into today's rally? The answer is a resounding yes. Sierra's stock appears to be grossly undervalued in light of momelotinib's commercial opportunity. Moreover, the market clearly wasn't expecting a positive phase 3 readout for this blood cancer drug. Aggressive investors might want to take advantage of this massive value gap while it still exists.

10 stocks we like better than Sierra Oncology, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Sierra Oncology, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of January 10, 2022

George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue